Biosynex Completes Acquisition of Chembio Diagnostics, Inc.
Summary
Biosynex has completed its acquisition of Chembio Diagnostics and now controls the company as a wholly owned indirect subsidiary. The deal gives Biosynex direct access to the North American market and expands its rapid diagnostic test portfolio. The combined company expects operational synergies in procurement, R&D, logistics, and production. Chembio’s FDA-cleared and WHO-prequalified products should create additional international business opportunities for the group. Chembio’s shares have stopped trading on Nasdaq as a result of the merger.
Classifications
industries
Fintech & Banking
applications
Governance, risk and compliance
AskAI Classifications
Labels
Financial Technology
SaaS
Data Analytics Software
Linked Companies
Nasdaq, Inc.
$5M to $10M